Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia

William A. Wood, Stephanie J. Lee, Ruta Brazauskas, Zhiwei Wang, Mahmoud D. Aljurf, Karen K. Ballen, David K. Buchbinder, Jason Dehn, Cesar O. Freytes, Hillard M. Lazarus, Charles F. LeMaistre, Paulette Mehta, David Szwajcer, Steven Joffe, Navneet S. Majhail

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.

Original languageEnglish (US)
Pages (from-to)829-836
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Homologous Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Young Adult
Survival
Cell Transplantation
Transplantation
Pediatrics
Survival Rate
Age Groups
Recurrence
Mortality
Neoplasms

Keywords

  • Adolescent and young adults
  • Allogeneic
  • Hematopoietic cell transplantation
  • Survival

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia. / Wood, William A.; Lee, Stephanie J.; Brazauskas, Ruta; Wang, Zhiwei; Aljurf, Mahmoud D.; Ballen, Karen K.; Buchbinder, David K.; Dehn, Jason; Freytes, Cesar O.; Lazarus, Hillard M.; LeMaistre, Charles F.; Mehta, Paulette; Szwajcer, David; Joffe, Steven; Majhail, Navneet S.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 6, 2014, p. 829-836.

Research output: Contribution to journalArticle

Wood, WA, Lee, SJ, Brazauskas, R, Wang, Z, Aljurf, MD, Ballen, KK, Buchbinder, DK, Dehn, J, Freytes, CO, Lazarus, HM, LeMaistre, CF, Mehta, P, Szwajcer, D, Joffe, S & Majhail, NS 2014, 'Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia', Biology of Blood and Marrow Transplantation, vol. 20, no. 6, pp. 829-836. https://doi.org/10.1016/j.bbmt.2014.02.021
Wood, William A. ; Lee, Stephanie J. ; Brazauskas, Ruta ; Wang, Zhiwei ; Aljurf, Mahmoud D. ; Ballen, Karen K. ; Buchbinder, David K. ; Dehn, Jason ; Freytes, Cesar O. ; Lazarus, Hillard M. ; LeMaistre, Charles F. ; Mehta, Paulette ; Szwajcer, David ; Joffe, Steven ; Majhail, Navneet S. / Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 6. pp. 829-836.
@article{cb93dc9411214ac5aa942eb1b71bce4e,
title = "Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia",
abstract = "Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.",
keywords = "Adolescent and young adults, Allogeneic, Hematopoietic cell transplantation, Survival",
author = "Wood, {William A.} and Lee, {Stephanie J.} and Ruta Brazauskas and Zhiwei Wang and Aljurf, {Mahmoud D.} and Ballen, {Karen K.} and Buchbinder, {David K.} and Jason Dehn and Freytes, {Cesar O.} and Lazarus, {Hillard M.} and LeMaistre, {Charles F.} and Paulette Mehta and David Szwajcer and Steven Joffe and Majhail, {Navneet S.}",
year = "2014",
doi = "10.1016/j.bbmt.2014.02.021",
language = "English (US)",
volume = "20",
pages = "829--836",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia

AU - Wood, William A.

AU - Lee, Stephanie J.

AU - Brazauskas, Ruta

AU - Wang, Zhiwei

AU - Aljurf, Mahmoud D.

AU - Ballen, Karen K.

AU - Buchbinder, David K.

AU - Dehn, Jason

AU - Freytes, Cesar O.

AU - Lazarus, Hillard M.

AU - LeMaistre, Charles F.

AU - Mehta, Paulette

AU - Szwajcer, David

AU - Joffe, Steven

AU - Majhail, Navneet S.

PY - 2014

Y1 - 2014

N2 - Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.

AB - Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.

KW - Adolescent and young adults

KW - Allogeneic

KW - Hematopoietic cell transplantation

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84899943649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899943649&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.02.021

DO - 10.1016/j.bbmt.2014.02.021

M3 - Article

C2 - 24607554

AN - SCOPUS:84899943649

VL - 20

SP - 829

EP - 836

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -